Clinical Trials Directory

Trials / Terminated

TerminatedNCT00014651

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Vapreotide in Pancreas Surgery: A Double-Blind, Placebo-Controlled, Randomized Study of Vapreotide to Prevent Post-Surgical Complications in Patients Undergoing Elective Pancreatic Resection Grant Application Title: Vapreotide to Prevent Complications of Pancreatic Resection

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection. PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works compared to a placebo in preventing complications in patients undergoing surgery for pancreatic cancer.

Detailed description

OBJECTIVES: I. Compare the efficacy of vapreotide versus placebo in reducing postoperative pancreatic complications in patients undergoing elective pancreatic resection. II. Compare the postoperative complications occurring within 45 days after surgery unrelated to the pancreas, days of hospitalization and survival at 45 days after surgery, number of rehospitalizations, and number of postoperative blood units or packed red blood cells administered in patients treated with these regimens. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to one of two treatment arms. Arm I: Patients undergo surgical resection on day 1 and receive vapreotide subcutaneously twice daily on days 1-7. Arm II: Patients undergo surgical resection and receive a placebo as in arm I. Patients are followed at days 28 and 45. PROJECTED ACCRUAL: A total of 580 patients (290 per arm) will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGvapreotide
PROCEDUREconventional surgery

Timeline

Start date
2001-03-01
Primary completion
2001-03-01
Completion
2002-04-01
First posted
2004-05-05
Last updated
2010-08-10

Locations

18 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00014651. Inclusion in this directory is not an endorsement.